FUNDAMENTALS · Fundamentals · AU Healthcare

Optiscan Imaging (OIL) Fundamentals 2026 — Revenue Analysis | SniperIQ

Optiscan Imaging (OIL) is a AU-listed Healthcare company in Medical - Instruments & Supplies with a market capitalization of A

62M, trading at A$0.15 on the ASX. This SniperIQ fundamentals page covers Optiscan Imaging's valuation, profitability (net margin -571.5%), revenue (A$4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapA
62M
Net Margin-571.5%
Revenue (FY25)A$4M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Optiscan Imaging's market cap?

Optiscan Imaging (OIL) has a market capitalization of approximately A

62M, trading at A$0.15 on the ASX. Market cap moves with the live share price.

What is Optiscan Imaging's P/E ratio?

Optiscan Imaging's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 6.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Optiscan Imaging?

Optiscan Imaging runs a net profit margin of -571.5%, a gross margin of 56.4%, and an operating margin of -672.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Optiscan Imaging generate?

Optiscan Imaging reported revenue of A$4M for fiscal year 2025, with net income of -A$6M and earnings per share (EPS) of -0.0076. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Optiscan Imaging pay a dividend?

Optiscan Imaging does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Optiscan Imaging financially healthy?

Optiscan Imaging carries a debt-to-equity ratio of 0.12x and a current ratio of 14.01x, with a market beta of 0.08. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Optiscan Imaging a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Optiscan Imaging (OIL) the key facts are: market cap A

62M, revenue A$4M, 52-week range 0.078461-0.16. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Optiscan Imaging's full fundamentals live

Get Optiscan Imaging's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Evommune (EVMN) fundamentals · Orthocell (OCC) fundamentals · AVITA Medical (AVH) fundamentals · ADC Therapeutics (ADCT) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons